1,25(OH)2D3 has been shown to suppress mitogen-stimulated IgG production in peripheral blood mononuclear cells from both healthy individuals and inactive SLE patients, indicating a direct inhibitory effect on IgG synthesis (180)
Key findings: Prescribing trends Using a subset of Truveta Data, Truveta Research identified people who were prescribed a GLP-1 RA between January 1, 2019 and March 31, 2026
This research was supported by grants from the following Swedish foundations: Hjrnfonden (Swedish Brain Foundation), Gun och Bertil Stohnes Stiftelse, Karolinska Institutets Foundation for geriatric research, Loo and Hans Ostermans Foundation, ke Wiberg Foundation, Svenska Lundbeck-stiftelsen, Demensfrbundet, Alzheimer Foundation
Several other molecules/companies are seeking licensing approval for obesity, noticeably tirzepatide (Mounjaro by Eli Lilly), a combined GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) agonist, both of which stimulate insulin secretion
A practical approach is to track pre-meal and 2-hour after-meal readings for a few days before and after dose adjustments
Current areas of investigation include: These are research directions, not established treatment outcomes
